Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) rose 1.3% during mid-day trading on Tuesday . The company traded as high as $3.24 and last traded at $3.22, with a volume of 129,829 shares. The stock had previously closed at $3.18.

A number of equities research analysts have weighed in on the company. Zacks Investment Research lowered Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 19th. Piper Jaffray Cos. decreased their target price on Anthera Pharmaceuticals from $14.00 to $10.00 and set an “overweight” rating for the company in a research report on Friday, March 11th. Jefferies Group reaffirmed a “buy” rating on shares of Anthera Pharmaceuticals in a research report on Thursday, June 30th. Finally, FBR & Co reaffirmed a “hold” rating on shares of Anthera Pharmaceuticals in a research report on Monday, June 20th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $9.50.

The stock’s market capitalization is $135.67 million. The firm’s 50 day moving average price is $3.37 and its 200 day moving average price is $3.53.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.01. On average, equities research analysts predict that Anthera Pharmaceuticals Inc. will post ($1.25) earnings per share for the current year.

Anthera Pharmaceuticals Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.